You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 300 No. 24, December 24/31, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Nutritional and Metabolic Disorders, Other
 •Cardiovascular System
 •Statistics and Research Methods
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The WENBIT study by Dr Ebbing and colleagues1 appears to refute the hypothesis of homocysteine as a cardiovascular risk factor. However, some important aspects were not considered in the article's discussion.

Homocysteine is a long-term risk factor. In the Gothenburg study,2 women with a high homocysteine level showed a higher mortality only after a follow-up of more than 15 years. Thus, short-term follow-up after cardiovascular events will probably not be able to demonstrate a benefit of B vitamins.

Furthermore, there seems to be no continuous correlation between homocysteine and cardiovascular risk below a threshold of homocysteine level of 12 µmol/L.2 In prospective studies, only participants in the highest quintile of baseline homocysteine had a significantly increased risk.3 In the WENBIT study, the mean homocysteine level at baseline was so low (approximately 11 µmol/L) that this would not be expected to act as a risk factor at all. . . . [Full Text of this Article]

Johannes Scholl, MD
scholl@preventionfirst.de
Prevention First–Private Practice for Preventive Medicine
Munich, Germany



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
, , , , , , , , and
JAMA. ;300():795-804.
FULL TEXT  

RELATED LETTERS

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
, , and
JAMA. ;300():2852-2852.
FULL TEXT  

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease
, , and
JAMA. ;300():2852-2853.
FULL TEXT  

Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease--Reply
, , and
JAMA. ;300():2853-2854.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.